Back to Prevention

Who Should Avoid Cabotegravir?

Who Should Avoid Cabotegravir?
Bareback Guide 31 August 2026

Cabotegravir suits people for whom daily tablets are the obstacle. It is a poor fit for several situations, and recognising which you are in matters more than with an oral drug, because an injection cannot be undone.

Who is excluded by interactions?

Anyone taking rifampicin or rifapentine for tuberculosis, and anyone on a strong enzyme-inducing anticonvulsant such as carbamazepine or phenytoin. These reduce levels enough to risk failure, and with an injectable the exposure cannot be reversed.

Who is excluded by attendance?

Anyone who cannot reliably attend appointments within the dosing window. This is not a judgement about circumstances but a practical reality: irregular injections produce periods of sub-protective drug levels, which is worse than reliably taken tablets and carries a resistance risk.

What situations make that difficult?

Frequent travel, unstable housing, shift work that clashes with clinic hours, or a life that is chaotic for any reason. None of these rule anyone out permanently, and they are worth discussing honestly beforehand rather than discovering after two missed appointments.

Who cannot use it for treatment?

Anyone whose viral load is not already suppressed. Injectable treatment is a switch option for people already stable, not a way to start. Anyone with known resistance to integrase inhibitors or to rilpivirine is also unsuitable, since the regimen depends on both being fully active.

What about hepatitis B?

An important point for treatment. Cabotegravir with rilpivirine has no activity against hepatitis B, so anyone with chronic hepatitis B who switches from a tenofovir-containing regimen would lose that cover and risk a flare. Those regimens are generally not suitable in that situation.

What about previous reactions?

Any suspected hypersensitivity to cabotegravir or rilpivirine rules out the injectable regimen. Because the drug persists for months, previous serious reactions to medicines generally are a reason to consider an oral lead-in first.

What about people with bleeding disorders?

Intramuscular injections require care where clotting is impaired or where someone is anticoagulated. Not an absolute barrier, and something to raise so that it can be planned rather than discovered.

What about pregnancy?

Data are more limited than for older drugs, and the long tail means the drug persists for months after stopping. Anyone pregnant or planning a pregnancy should discuss it with their clinic rather than making a decision alone.

What about body weight?

Some analyses have looked at whether higher body weight affects drug levels and outcomes, without producing a clear restriction. It is a consideration a clinician may factor in rather than a reason anyone is refused.

What are the alternatives for prevention?

Daily oral PrEP with tenofovir disoproxil and emtricitabine, or event-based dosing for anal sex. Lenacapavir, given twice yearly, where available. Condoms and a partner with a sustained undetectable viral load remain fully effective.

What are the alternatives for treatment?

Conventional daily single-tablet regimens, of which several are extremely well tolerated and require nothing more than one tablet a day. If the difficulty with tablets is practical rather than absolute, it is worth exploring what specifically is getting in the way before switching to an injectable schedule.

Is it worth trying the oral form first?

Where tolerability is uncertain, yes. A month of oral cabotegravir gives some indication of how you will respond before committing to a depot that cannot be removed. Practice varies and it is reasonable to ask for it.

What should you tell your clinic?

Everything you take, any previous drug reactions, whether you have hepatitis B, and an honest account of how reliably you can attend. The last of these is the one people understate, and it is the one that most determines whether this suits you.

What if it is the only option available?

Rarely the case. HIV medicine now has enough options that almost every situation has an alternative, and where choices genuinely are limited a specialist will construct something around your resistance profile. Being told there is nothing else is worth a second opinion.